CN104435497A - Traditional Chinese medicinal composition for treating diabetic feet - Google Patents
Traditional Chinese medicinal composition for treating diabetic feet Download PDFInfo
- Publication number
- CN104435497A CN104435497A CN201410626125.5A CN201410626125A CN104435497A CN 104435497 A CN104435497 A CN 104435497A CN 201410626125 A CN201410626125 A CN 201410626125A CN 104435497 A CN104435497 A CN 104435497A
- Authority
- CN
- China
- Prior art keywords
- parts
- raw material
- medicinal raw
- chinese medicine
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008960 Diabetic foot Diseases 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 79
- 239000003814 drug Substances 0.000 claims abstract description 45
- 239000009286 sanguis draxonis Substances 0.000 claims description 15
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 15
- 230000000694 effects Effects 0.000 abstract description 17
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 241001165494 Rhodiola Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 239000000706 filtrate Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000000284 extract Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 206010040943 Skin Ulcer Diseases 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 231100000019 skin ulcer Toxicity 0.000 description 10
- 238000000605 extraction Methods 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000002266 amputation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010012665 Diabetic gangrene Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicine, relates to a tradtional Chinese medicinal composition, and particularly relates to a tradtional Chinese medicinal composition for treating diabetic feet. The tradtional Chinese medicinal composition for treating diabetic feet is prepared from the following medicinal raw materials in parts by weight: 10-15 parts of rhodiola, 10-15 parts of root of red-rooted salvia, 6-10 parts of resina draconis and 6-10 parts of houttuynia. The traditional Chinese medicinal composition for treating diabetic feet, prepared by combining four medicinal raw materials according to a proportion, has a synergic function, has short treatment course and good treatment effect when being used for treating the diabetic feet and does not have side effect on the body of a patient.
Description
Technical field
The invention belongs to medical art, relate to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition for the treatment of diabetic foot.
Background technology
The metabolic disease of diabetes to be one group with hyperglycemia be feature, is that China's sickness rate is high, endangers one of serious epidemic diseases.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction, causes various diabetic complication.According to statistics, the mortality rate of diabetic complication is only second to cardiovascular diseases, cerebrovascular and tumor, occupies the 4th.Diabetes mellitus in China patient populations close to 4,000 ten thousand people, occupies third place in the world, compared with 0.7% of the eighties in 20th century, increases 5 times.
Diabetic foot is one of diabetes common complication, is due to diabetics because the concentration of glucose in blood is too high, and human body defensive ability/resistance ability declines, and the supply of blood flow of lower limb and foot is not enough, causes foot to resist the disease of the decline of infection and wound self-healing ability.Once wound, ulcer and infection appear in foot or lower limb, as treated not in time, be often difficult to healing, a slight wound will prolongedly not healed, wound scope rapid expansion, even downright bad, amputation of finally having to.
Diabetic foot is most commonly in diabetes medical history length, long-term blood glucose controls bad middle-aged and elderly people, is one of diabetes severe complication, and sickness rate 15% ~ 20% is the main cause that amputation disables.The performance of diabetes foot disease initial stage is numb, send out cool, sensory capacity reduces, easily injured, shallow table wound not easily heal, often easily out in the cold, later stage deterioration quickly, probably faces amputation in one week.
The Therapeutic Method major control blood glucose of current doctor trained in Western medicine aspect treatment diabetic foot, blood fat and blood pressure, improve blood circulation, improve peripheral neuropathy, use antibiotic anti-infective therapy, to the process etc. of changing dressings of ulcer wound surface.Chemical drugs does not also have the special medicine for diabetic foot, and general treatment method is conservative symptomatic treatment, and simultaneously conventional chemicals has obvious side effect, and diabetics needs lifelong medication, and long-term prescription can exert an adverse impact to health.
Diabetic foot is also known as diabetic gangrene, the traditional Chinese medical science thinks diabetic foot and thromboangiitis obliterans, atherosclerotic occlusive disease belongs to the traditional Chinese medical science " necrosis " category together, be mainly deficiency of both QI and YIN, obstruction of collaterals by blood stasis, QI and blood can not caused by sensible extremity, the Chinese medicine of suiting the medicine to the illness is adopted to treat diabetics, the blood viscosity of diabetics can be reduced, increase the LBF of diabetics, remove the damage factor of blood capillary and local organization, make local blood for improving, be conducive to the recovery of diabetic gangrene, the traditional Chinese medical science takes thought as the leading factor with the similar sight of Overall View, with the physiology of zang-fu differentiation, based on pathology, take determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs as diagnosis and treatment foundation, to Hu patient medication.Because it is little to the side effect of the person, and demand commercially constantly increases.
Summary of the invention
Object of the present invention provides a kind of Chinese medicine composition for the treatment of diabetic foot, this Chinese medicine composition good effect, little to person side effect.
In order to realize foregoing invention object, the invention provides following technical scheme:
Treating a Chinese medicine composition for diabetic foot, is be prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 10 ~ 15 parts, Radix Salviae Miltiorrhizae 10 ~ 15 parts, Sanguis Draxonis 6 ~ 12 parts, Herba Houttuyniae 6 ~ 12 parts.Described various medicinal raw material is the Chinese crude drug meeting country or provincial standard and specify.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Radix Rhodiolae is 12 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Radix Salviae Miltiorrhizae is 12 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Sanguis Draxonis is 10 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Herba Houttuyniae is 10 parts.
The Chinese medicine composition for the treatment of diabetic foot of the present invention, Traditional Chinese medicine extraction method conveniently can extract the active component of medicinal raw material, add pharmaceutically acceptable carrier or/and adjuvant, as starch, dextrin, microcrystalline cellulose, amylum pregelatinisatum, magnesium stearate, micropowder silica gel, sucrose, carboxymethyl starch sodium, hydroxypropyl emthylcellulose, vegetable oil, lecithin, Polyethylene Glycol, propylene glycol, ethyl hydroxybenzoate etc., make dosage form suitable on pharmaceutics, as granule, tablet, hard capsule, oral liquid, soft capsule, drop pill, water pill etc.
Compared with prior art, beneficial effect of the present invention:
The present invention treats the Chinese medicine composition of diabetic foot, and after pressing formula proportion combination by Radix Rhodiolae, Radix Salviae Miltiorrhizae, Sanguis Draxonis, Herba Houttuyniae, Traditional Chinese medicine extraction method conveniently obtains after extracting the active component of medicinal raw material.Wherein, Radix Rhodiolae has QI invigorating lung heat clearing, Fructus Alpiniae Oxyphyllae is nourished heart, effect of hemostasis with astringents, dissipating blood stasis for subsidence of swelling.Cure mainly deficiency of vital energy and physically weak, after being ill fear of cold, shortness of breath and fatigue, cough due to lung-heat, spitting of blood, leucorrhea diarrhoea, traumatic injury etc.; Radix Salviae Miltiorrhizae has stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, the effect of the relieving restlessness that clears away heart-fire.For menoxenia, amenorrhea dysmenorrhea, lump in the abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection swells and ache, dysphoria and insomnia; Hepatosplenomegaly, angina pectoris; Sanguis Draxonis has dissipating blood stasis analgesic therapy; Hemostasis; Effect of promoting tissue regeneration and ulcer healing, cures mainly and plays damage; Ecchymoma due to internal injury; Dysmenorrhea; Postpartum stagnation is suffered from abdominal pain; Continuous bleeding due to traumatic injury; Scrofula; Ecthyma unhealed for long time and hemorrhoid; Herba Houttuyniae acrid in the mouth, cold, return lung meridian.Heat-clearing and toxic substances removing, detumescence can treat skin ulcer, promoting urination to remove dampness, clearing away heat to cure dysentery, invigorating the stomach and promoting digestion, by the lung abscess, sore swollen toxin, hemorrhoidal hemorrhage, retention of heat in the spleen and stomach etc. of controlling excess-heat, pyretic toxicity, damp, disease heat are trouble.Through the Chinese medicine compound medicine efficacy screening Platform Screening of application initiative, 4 taste medicinal raw materials, by after described weight proportion mixing, have the function of Synergistic, can significantly improve the curative effect of Chinese medicine composition, be used for the treatment of diabetic foot instant effect, good effect, show through clinical research, Chinese medicine composition of the present invention is used for the treatment of diabetic foot, can reduce wound surface area, reduce amputation rate, shorten and treat the course for the treatment of, total effective rate reaches more than 85%, and does not find apparent side effect and untoward reaction.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on content of the present invention all belong to scope of the present invention.
The percentage composition of the embodiment of the present invention and comparative example ethanol used, if no special instructions, is volumn concentration, and ethanol is its aqueous solution.
Embodiment 1
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 12 parts, Radix Salviae Miltiorrhizae 12 parts, Sanguis Draxonis 10 parts, Herba Houttuyniae 10 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, 2 times are decocted with water in medicinal raw material, be followed successively by medicinal raw material volume by water volume 10 times and 8 times that decoct for 2 times, 2 times decocting time is followed successively by 1.5 hours and 1 hour, filters and collects filtrate after each decoction; Merge 2 filtrates, obtain the extracting solution of embodiment 1 medicinal raw material, the extracting solution of embodiment 1 medicinal raw material is concentrated into relative density 1.20 (80 DEG C), obtains the extract of embodiment 1.
In above-mentioned extract, add the soluble starch of extract 2 times of weight, granulation, drying, be distributed into bag, obtain the Chinese medicinal composition granules that embodiment 1 treats diabetic foot.
Embodiment 2
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 10 parts, Radix Salviae Miltiorrhizae 10 parts, Sanguis Draxonis 12 parts, Herba Houttuyniae 12 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, 3 times are decocted with water in medicinal raw material, what decoct for 3 times is followed successively by 10 times amount of medicinal raw material volume, 8 times amount and 8 times amount by water volume, 3 decocting times are followed successively by 1.5 hours, 1 hour and 1 hour, each decoct after filters and collects filtrate; Merge 3 filtrates, obtain the extract of embodiment 2 medicinal raw material.
Embodiment 3
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 15 parts, Radix Salviae Miltiorrhizae 15 parts, Sanguis Draxonis 12 parts, Herba Houttuyniae 12 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, 70% alcohol reflux 3 times are added in medicinal raw material, the 70% ethanol volume used of 3 backflows is followed successively by 10 times, 8 times and 8 times of medicinal raw material volume, 3 return times are followed successively by 1.5 hours, 1 hour and 1 hour, refluxed rear filtration collect filtrate at every turn; Merge 3 filtrates and the ethanol removed in filtrate, obtain the extract of embodiment 3 medicinal raw material.
Embodiment 4
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 10 parts, Radix Salviae Miltiorrhizae 10 parts, Sanguis Draxonis 6 parts, Herba Houttuyniae 6 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, medicinal raw material is made powder and mix homogeneously, with 80% ethanol percolate extraction 8h, the volume of described 80% ethanol is 10 times of medicinal raw material volume, collect the liquid after percolation and filter, collect filtrate and reclaim the extract that ethanol obtains embodiment 4 medicinal raw material.
Embodiment 5
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 10 parts, Radix Salviae Miltiorrhizae 10 parts, Sanguis Draxonis 12 parts, Herba Houttuyniae 12 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, extraction is decocted with water 3 times after being mixed by medicinal raw material, be followed successively by medicinal raw material volume by water volume 10 times, 8 times and 8 times that decoct for 3 times, 3 decocting times are followed successively by 1.5 hours, 1 hour and 1 hour, each decoct after filters and collects filtrate; Merge 3 filtrates, obtain the extract of embodiment 5 medicinal raw material.
Embodiment 6
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 10 parts, Radix Salviae Miltiorrhizae 12 parts, Sanguis Draxonis 6 parts, Herba Houttuyniae 10 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, 65% alcohol reflux 2 times are added in medicinal raw material, the volume of 65% ethanol that 2 backflows are used is followed successively by 10 times and 8 times of medicinal raw material volume, 2 times return time is followed successively by 1.5 hours and 1 hour, and refluxed rear filtration collect filtrate at every turn; Merge 2 filtrates, the ethanol in removing filtrate, obtains the extract of embodiment 6 medicinal raw material.
Embodiment 7
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 12 parts, Radix Salviae Miltiorrhizae 10 parts, Sanguis Draxonis 8 parts, Herba Houttuyniae 8 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, extraction is decocted with water 3 times after being mixed by medicinal raw material, be followed successively by medicinal raw material volume by water volume 10 times, 8 times and 8 times that decoct for 3 times, decocting time is followed successively by 1.5 hours, 1 hour and 1 hour, each decoct after filters and collects filtrate; Merge 3 filtrates, obtain the extract of embodiment 7 medicinal raw material.
Embodiment 8
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 12 parts, Radix Salviae Miltiorrhizae 10 parts, Sanguis Draxonis 10 parts, Herba Houttuyniae 8 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, extraction is decocted with water 2 times after being mixed by medicinal raw material, be followed successively by medicinal raw material volume by water volume 10 times and 8 times that decoct for 2 times, 2 times decocting time is followed successively by 1.5 hours and 1 hour, filters and collects filtrate after each decoction; Merge 2 filtrates, obtain the extract of embodiment 8 medicinal raw material.
Comparative example 1
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 12 parts, Radix Salviae Miltiorrhizae 12 parts, Sanguis Draxonis 10 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, extraction is decocted with water 2 times after being mixed by medicinal raw material, be followed successively by medicinal raw material volume by water volume 10 times and 8 times that decoct for 2 times, 2 times decocting time is followed successively by 1.5 hours and 1 hour, filters and collects filtrate after each decoction; Merge 2 filtrates, obtain the extract of comparative example 1 medicinal raw material.
Comparative example 2
The Chinese medicine composition of the treatment diabetic foot of the present embodiment is prepared from by the medicinal raw material of following weight proportion: Radix Rhodiolae 12 parts, Radix Salviae Miltiorrhizae 12 parts, Herba Houttuyniae 10 parts.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, extraction is decocted with water 2 times after being mixed by medicinal raw material, 10 times and 8 times amount being followed successively by medicinal raw material volume by water volume that decoct for 2 times, 2 times decocting time is followed successively by 1.5 hours and 1 hour, filters and collects filtrate after each decoction; Merge 2 filtrates, obtain the extract of comparative example 2 medicinal raw material.
Pharmacodynamics test proves:
For proving the efficacy and saferry of medicine of the present invention, inventor have selected the patient that 180 examples are diagnosed as diabetic foot, and medicine group all cases of the present invention all meets the diagnostic criteria (draft) of (acral necrosis) that the national academic conference of Chinese Medical Association first is formulated.In above-mentioned patient, according to Wagner grade scale, 0 grade of 40 example (there is the foot that ulcer of foot risk factor occurs, but at present without ulcer); 1 grade of 60 example (there is ulcer on surface, clinically without infection); 2 grade of 42 example (have darker ulcer, often merge soft tissue infection, the infection without abscess or bone); 3 grades of (deep infection, with osseous tissue pathological changes or abscess) 38; 4 grade of 10 example (circumscribed gangrene).
Above-mentioned patient at different levels is divided into 3 groups at random, often organizes each 60 examples of patient; Wherein take the extract obtained by embodiment 1 medicinal raw material proportioning and preparation method for first group, second group of patient takes comparative example 1 medicinal raw material proportioning and the obtained extract of preparation method, 3rd group of patient takes comparative example 2 medicinal raw material proportioning and the obtained extract of preparation method, daily potion, medicinal raw material weight and embodiment 1 medicinal raw material of every potion are equal in weight, points 3 times oral, coordinate following Therapeutic Method while taking medicine: 1. insulinize, make glycemic control between 7 ~ 9mmol/L; 2. concurrent infection person, gives antiinflammatory and symptomatic treatment; 3. corresponding process is done for the sufficient wound surface of trouble.Above-mentioned patient is carried out to the clinical research treatment of 3 months.
Take medicine forward and backward, carry out clinical observation to patient, observation index comprises following aspect:
(1) safety indexes: the large conventional and electrocardiogram of blood pressure, pulse, blood, urine, excrement three, liver, kidney brake check.
(2) health giving quality index:
A. general curative effect compares
B. skin ulcer face area, with the product representation of greatest length (cm) × Breadth Maximum (cm), if any many places wound surface, the record gross area.
(3) untoward reaction is observed: comprise gastrointestinal reaction, nervous system abnormality, skin allergy etc.
The selected 180 routine patients being diagnosed as diabetic foot are carried out to clinical treatment, the observation of 3 months, in therapeutic process, each group is showed no obvious adverse reaction, Patients Before And After electrocardiogram of taking medicine, Liver and kidney function, and blood, routine urinalysis are without significant change; Efficacy determination is carried out after treatment in 3 months expires; Outcome measure comprises healing, effective, effective and invalid four grades; Wherein, cure: wound surface all healed; Effective: more than two ranks that take a turn for the better; Effective: more than the rank that takes a turn for the better; Invalid: unchanged or gangrene increases the weight of.
Result:
Cure 25 examples for first group, effective 22 examples, effective 10 examples, invalid 3 examples; Total effective rate is 95%; Before treatment, average skin ulcer face area is 29.23 ± 12.41cm
2, after treatment, average skin ulcer face area is reduced to 8.12 ± 4.01cm
2, check through paired data t, P<0.01, has significant difference, and first group evident in efficacy;
Cure 15 examples for second group, effective 18 examples, effective 15 examples, invalid 12 examples; Total effective rate is 80%; Before treatment, average skin ulcer face area is 28.04 ± 13.63cm
2, after treatment, average skin ulcer face area is reduced to 15.77 ± 5.87cm
2, check through paired data t, P > 0.05, there was no significant difference, second group of therapeutic effect is poor;
Cure 14 examples for 3rd group, effective 16 examples, effective 15 examples, invalid 15 examples; Total effective rate is 75%; Before treatment, average skin ulcer face area is 28.58 ± 14.26cm
2, after treatment, average skin ulcer face area is reduced to 14.62 ± 7.22cm
2, check through paired data t, P > 0.05, there was no significant difference, the 3rd group of therapeutic effect is poor.
Statistical analysis is carried out to average skin ulcer face area after first group and second group for the treatment of, first group compared with second group, p<0.05, has significant difference; Statistical analysis is carried out to average skin ulcer face area after first group and the 3rd group for the treatment of, first group compared with the 3rd group, p<0.05, has significant difference; Learnt by the experimental result statistical data of first group, second group and the 3rd group, second group is obviously reduced with relative first group of the therapeutic effect of the 3rd group.
To sum up, the present invention treats the Chinese medicine composition of diabetic foot, treatment diabetic foot good effect, instant effect and having no side effect to health, and 4 taste medicinal raw materials press after formula proportion combines, and have Synergistic function; Reduce the flavour of a drug number in formula, the curative effect for the treatment of diabetic foot all can obviously reduce, and as in above-mentioned clinical observation, second group is obviously reduced with relative first group of the therapeutic effect of the 3rd group.
Claims (5)
1. treat a Chinese medicine composition for diabetic foot, it is characterized in that: it is made up of the medicinal raw material of following weight proportion: Radix Rhodiolae 10 ~ 15 parts, Radix Salviae Miltiorrhizae 10 ~ 15 parts, Sanguis Draxonis 6 ~ 12 parts, Herba Houttuyniae 6 ~ 12 parts.
2. Chinese medicine composition according to claim 1, is characterized in that: part by weight shared by Radix Rhodiolae is 12 parts.
3. Chinese medicine composition according to claim 1, is characterized in that: part by weight shared by Radix Salviae Miltiorrhizae is 12 parts.
4. Chinese medicine composition according to claim 1, is characterized in that: part by weight shared by Sanguis Draxonis is 10 parts.
5. Chinese medicine composition according to claim 1, is characterized in that: part by weight shared by Herba Houttuyniae is 10 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626125.5A CN104435497A (en) | 2014-11-07 | 2014-11-07 | Traditional Chinese medicinal composition for treating diabetic feet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626125.5A CN104435497A (en) | 2014-11-07 | 2014-11-07 | Traditional Chinese medicinal composition for treating diabetic feet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104435497A true CN104435497A (en) | 2015-03-25 |
Family
ID=52882758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410626125.5A Pending CN104435497A (en) | 2014-11-07 | 2014-11-07 | Traditional Chinese medicinal composition for treating diabetic feet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435497A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109223983A (en) * | 2018-11-23 | 2019-01-18 | 王晶 | The Chinese medicine composition and pharmaceutical preparation and preparation method and application for treating diabetic foot |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1745810A (en) * | 2005-10-17 | 2006-03-15 | 高春 | Chinese medicinal pill for treating diabetes mellitus |
| CN102389501A (en) * | 2011-09-03 | 2012-03-28 | 北京绿源求证科技发展有限责任公司 | Chinese medicine for treating diabetic peripheral neuropathy |
-
2014
- 2014-11-07 CN CN201410626125.5A patent/CN104435497A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1745810A (en) * | 2005-10-17 | 2006-03-15 | 高春 | Chinese medicinal pill for treating diabetes mellitus |
| CN102389501A (en) * | 2011-09-03 | 2012-03-28 | 北京绿源求证科技发展有限责任公司 | Chinese medicine for treating diabetic peripheral neuropathy |
Non-Patent Citations (1)
| Title |
|---|
| 韩曼: "《难病奇方系列丛书 当归四逆汤》", 31 January 2013 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109223983A (en) * | 2018-11-23 | 2019-01-18 | 王晶 | The Chinese medicine composition and pharmaceutical preparation and preparation method and application for treating diabetic foot |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258658A (en) | Plaster for invigorating blood circulation and relieving pain | |
| CN117959394B (en) | Use of Shenqi Tongmai preparation in preparing medicine for preventing and treating diabetic neuropathy | |
| CN1541676A (en) | Health care medicine for enriching blood in puerperium and its preparation and uses | |
| CN102688361B (en) | A kind of Chinese medicine composition treating dysmenorrhea and preparation thereof | |
| CN101850044B (en) | Medicament for treating peptic ulcer and reflux esophagitis and preparation method thereof | |
| CN102940693B (en) | Medicine composition for treating diabetic foot | |
| CN103301310A (en) | Blood glucose-reducing Chinese medicine preparation and preparation method thereof | |
| CN102940757B (en) | Medicine composition for treating diabetic foot | |
| CN102940677B (en) | Medicine composition for treating diabetic foot | |
| CN101628056B (en) | Compound composition for treating diabetic constipation | |
| CN1907394B (en) | Medicine for treating diabetes foot | |
| CN104548029A (en) | Pharmaceutical composition for treating epigastric pain | |
| CN104095915A (en) | Traditional Chinese medicine composition for treating diabetic foot | |
| CN1284593C (en) | Medicine for treating anaphylactoid purpura | |
| CN102940743B (en) | Medicine composition for treating diabetic foot | |
| CN104435167A (en) | Traditional Chinese medicine composition containing eupolyphaga for treating diabetic feet | |
| CN102940671B (en) | Medicine composition for treating diabetic foot | |
| CN101991804A (en) | External medicine for treating stomach disease | |
| CN105169078A (en) | Traditional Chinese medicinal composition for treating diabetes | |
| CN102961662B (en) | Medicine for treating gastric ulcer and preparation method thereof | |
| CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
| CN104367631A (en) | Traditional Chinese medicine composition containing tortoise plastron and used for treating diabetic foot | |
| CN104352585A (en) | Scorpion-containing traditional Chinese medicine composition for treating diabetic foot | |
| CN101391045B (en) | Traditional Chinese medicine compound preparation for treating migraine and general headache and preparation method thereof | |
| CN103860899B (en) | A kind of Chinese medicine composition treating diabetic foot |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150325 |
|
| RJ01 | Rejection of invention patent application after publication |